102 related articles for article (PubMed ID: 24412619)
1. Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Pircher A; Manzl C; Fiegl M; Popper H; Pirker R; Hilbe W
Lung Cancer; 2014 Mar; 83(3):408-10. PubMed ID: 24412619
[TBL] [Abstract][Full Text] [Related]
2. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF
Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
Cancer Discov; 2014 Nov; 4(11):OF18. PubMed ID: 25367959
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
[TBL] [Abstract][Full Text] [Related]
5. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
6. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT
Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492
[TBL] [Abstract][Full Text] [Related]
7. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
8. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
10. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
Faehling M; Eckert R; Kamp T; Kuom S; Griese U; Sträter J; Ott G; Spengler W
Lung Cancer; 2013 Jun; 80(3):306-12. PubMed ID: 23489557
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.
Cadranel J; Ruppert AM; Beau-Faller M; Wislez M
Crit Rev Oncol Hematol; 2013 Dec; 88(3):477-93. PubMed ID: 23911281
[TBL] [Abstract][Full Text] [Related]
12. Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Neoplasma; 2013; 60(4):425-31. PubMed ID: 23581415
[TBL] [Abstract][Full Text] [Related]
13. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.
Kao HF; Lin CC; Yang JC
Future Oncol; 2013 Jul; 9(7):991-1003. PubMed ID: 23837762
[TBL] [Abstract][Full Text] [Related]
14. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
Mariano C; Bosdet I; Karsan A; Ionescu D; Murray N; Laskin JJ; Zhai Y; Melosky B; Sun S; Ho C
Lung Cancer; 2014 Jan; 83(1):73-7. PubMed ID: 24192511
[TBL] [Abstract][Full Text] [Related]
15. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
16. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment.
Kim HR; Lee JC; Kim YC; Kim KS; Oh IJ; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Ryu JS; Jang SH; Son JW; Lee JE; Kim SY; Kim HJ; Lee KY
Lung Cancer; 2014 Feb; 83(2):252-8. PubMed ID: 24309368
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Rolfo C; Giovannetti E; Hong DS; Bivona T; Raez LE; Bronte G; Buffoni L; Reguart N; Santos ES; Germonpre P; Taron M; Passiglia F; Van Meerbeeck JP; Russo A; Peeters M; Gil-Bazo I; Pauwels P; Rosell R
Cancer Treat Rev; 2014 Sep; 40(8):990-1004. PubMed ID: 24953979
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
[TBL] [Abstract][Full Text] [Related]
20. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.
Yang JJ; Chen HJ; Yan HH; Zhang XC; Zhou Q; Su J; Wang Z; Xu CR; Huang YS; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Jiang BY; Dong S; Wu YL
Lung Cancer; 2013 Jan; 79(1):33-9. PubMed ID: 23079155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
